Literature DB >> 12946247

Skin reactions related to treatment with anticytokines, membrane receptor inhibitors and monoclonal antibodies.

O Dereure1.   

Abstract

Therapeutic monoclonal antibodies, soluble cytokines and receptors to cytokines, and inhibitors of tyrosine kinase, are currently used in an ever increasing number of patients with neoplastic and inflammatory disorders. Their cutaneous side effects are not always well known by physicians in charge of these new biotherapies. However, these side effects seem to be relatively frequent and may seriously disturb the patients or even represent a life-threatening event. Accordingly, it appears necessary for dermatologists and physicians using these therapies to be aware of the varied patterns of skin complications they may cause, in order to manage the treatment in the safest and most comfortable way for the patients.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12946247     DOI: 10.1517/14740338.2.5.467

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  2 in total

1.  Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia.

Authors:  J John Weems; James P Steinberg; Scott Filler; John W Baddley; G Ralph Corey; Priya Sampathkumar; Lisa Winston; Joseph F John; Christine J Kubin; Rohit Talwani; Thomas Moore; Joseph M Patti; Seth Hetherington; Michele Texter; Eric Wenzel; Violet A Kelley; Vance G Fowler
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

2.  Sirolimus as Long-term Graft-versus-host-disease Prophylaxis in Haploidentical Hematopoietic Stem Cell Transplant Recipients for Non-malignant Disorders is Associated with High Incidence of Acneiform Lesions.

Authors:  Aditi Chakrbarti; Sarita Rani Jaiswal; Suparno Chakrabarti
Journal:  Indian J Dermatol       Date:  2015 Nov-Dec       Impact factor: 1.494

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.